A phase 2 trial assessing clinical outcomes and safety for patients with unresectable advanced hepatocelluar carcinoma (HCC) treated with apatinib in combination with intensity modulated radiation therapy
Latest Information Update: 19 Jul 2021
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 19 Jul 2021 New trial record
- 08 Jun 2021 Results (Data cut off: February 1, 2021) presented at the 57th Annual Meeting of the American Society of Clinical Oncology